25,729 articles
Occult macular dystrophy
Occult macular dystrophy (OMD, Miyake disease, 三宅病) is a rare autosomal dominant retinal disease causing progressive central vision loss with a normal-appearing fundus, normal full-field ERG, attenuated focal macular ERG, and RP1L1 mutations.
Occupational Accidents
An occupational accident is a sudden, unforeseen event occurring during or in connection with work that results in injury, illness, or death, as defined by the International Labour Organization.
Occupational acne
Occupational acne, also called acne venenata, is work-related acne from oil, coal tar, or halogenated aromatics; chloracne, its most serious form, signals systemic poisoning by chloracnegens such as dioxins and PCBs.
Occupational contact dermatitis
Occupational contact dermatitis is skin inflammation caused by substances or wet conditions at work, mostly irritant, affecting the hands in up to 80% of cases.
Occupational disease
Occupational disease: a disease contracted from exposure to risk factors arising from work activity, defined by the ILO Protocol of 2002; recognized via causal criteria, listed nationally, compensated no-fault, and monitored through health surveillance.
Occupational Exposure
Occupational exposure: worker contact with physical, chemical, or biological workplace hazards, measured against occupational exposure limits (OELs, PELs, TLVs, RELs) such as 8-hour TWAs and controlled via the hierarchy of controls.
Occupational medicine
Occupational medicine: medical specialty for prevention, diagnosis, and management of work-related illness and injury, fitness-for-work assessment, health surveillance, and return-to-work practice, grounded in WHO and ILO standards.
Occupational therapist
Occupational therapist (OT): autonomous health professional helping people with injuries, illness, or disabilities perform daily living and work activities. Profession founded 1917; WFOT sets global education standards; US median pay $100,330, 15% projected growth 2025–2035.
Occupational therapy
Occupational therapy: health profession supporting participation in meaningful everyday occupations. Formalized 1917 in the US; global body WFOT founded 1952, 105 member organizations, WHO relations since 1959.
OCI-AML-2
OCI-AML-2 (CVCL_1619, DSMZ ACC-99) is a human acute myeloid leukemia cell line, FAB M4, established 1986 from a 65-year-old man's peripheral blood; carries DNMT3A R635W and KMT2A-AFDN fusion, used in AML drug and CRISPR studies.
Ociperlimab
Ociperlimab (BGB-A1217), BeiGene's humanized IgG1 anti-TIGIT checkpoint antibody with Fc-competent ADCC activity, tested with tislelizumab in AdvanTIG trials; phase 3 AdvanTIG-302 in NSCLC stopped for futility and lung cancer development was discontinued.
Ocrelizumab
Ocrelizumab (Ocrevus, Ocrevus Zunovo) is a CD20-directed monoclonal antibody depleting B cells, FDA-approved March 2017 for relapsing and primary progressive multiple sclerosis, dosed 600 mg IV every 24 weeks.
Ocriplasmin
Ocriplasmin (Jetrea, microplasmin), a recombinant truncated human plasmin serine protease, treats symptomatic vitreomacular adhesion by enzymatic vitreolysis via a single 125 µg intravitreal injection; FDA-approved 2012, EU authorization withdrawn 2023.
OCT-ORION trial
OCT-ORION (NCT01742507) was a 2018 randomized optical coherence tomography trial in 60 multivessel-disease patients comparing Resolute Integrity durable-polymer zotarolimus-eluting and BioMatrix biodegradable-polymer biolimus A9-eluting stents; the durable-polymer stent showed better strut coverage with similar clinical outcomes.
OCTAVE trial (NCT01458574)
OCTAVE Sustain (NCT01458574), also called the OCTAVE maintenance trial, was Pfizer's phase 3 trial of tofacitinib maintenance therapy in 593 ulcerative colitis responders, showing 34.3–40.6% remission at 52 weeks versus 11.1% placebo.
OCTAVE trial (NCT01458951)
OCTAVE Induction 2 (NCT01458951), also called the CP-690,550 OCTAVE study, was Pfizer's phase 3 trial of tofacitinib 10 mg twice daily for 8 weeks in 541 patients with moderate-to-severe ulcerative colitis; remission 16.6% vs 3.6% placebo.
OCTAVE trial (NCT01465763)
OCTAVE Induction 1 (NCT01465763) was a phase 3, placebo-controlled trial testing oral tofacitinib 10 mg twice daily as 8-week induction therapy for moderate-to-severe ulcerative colitis.
OCTAVE trial (NCT01470612)
OCTAVE Open (NCT01470612), also called the OCTAVE long-term extension trial, was Pfizer's phase 3 open-label extension of tofacitinib in ulcerative colitis: 944 patients, up to 7.0 years, stable safety with elevated herpes zoster rates and efficacy maintained to 36 months.
Octocog alfa
Octocog alfa is recombinant full-length human coagulation factor VIII for haemophilia A, sold as Advate (Takeda, 2003) and Kovaltry (Bayer); intravenous replacement therapy, prophylaxis, and surgery, not for von Willebrand disease.
Octreotide
Octreotide (Sandostatin) is a synthetic octapeptide somatostatin analogue synthesized at Sandoz in 1980 and FDA-approved in 1988. It inhibits GH, insulin, and gut hormone secretion, treating acromegaly and carcinoid syndrome, with LAR monthly and oral formulations.
Ocular albinism with late-onset sensorineural deafness
Ocular albinism with late-onset sensorineural deafness (OASD), also called ocular albinism with late-onset sensorineural hearing loss, is a rare X-linked disorder with severe vision impairment and moderately severe hearing loss appearing from adolescence to middle age.
Ocular anomalies-axonal neuropathy-developmental delay syndrome
Ocular anomalies-axonal neuropathy-developmental delay syndrome, or Harel-Yoon syndrome (HAYOS), is a rare ATAD3A (1p36.33) mitochondrial neurodevelopmental disorder with hypotonia, spasticity, optic atrophy, neuropathy, and cardiomyopathy; OMIM 617183.
Ocular biometry
Ocular biometry is the measurement of the eye's dimensions, chiefly corneal curvature, axial length, and anterior chamber depth, used to calculate intraocular lens power for cataract surgery.
Ocular cicatricial pemphigoid
Ocular cicatricial pemphigoid, also called ocular mucous membrane pemphigoid, is a chronic autoimmune subepithelial blistering disease causing progressive conjunctival scarring, affecting about 70% of MMP cases, diagnosed by direct immunofluorescence biopsy and treated with systemic immunosuppression.
Ocular dominance
Ocular dominance: behavioral preference for one eye and its cortical counterpart, ocular dominance columns in V1, described by Hubel and Wiesel; covers critical-period plasticity, deprivation, amblyopia, and the unsupported link to reading skill.
Ocular fluorophotometry
Ocular fluorophotometry, also known as vitreous fluorophotometry, is a technique that measures fluorescein concentration along the eye's axis to quantify blood-retinal barrier permeability and aqueous flow.
Ocular hypertension
Ocular hypertension is a condition in which the pressure inside the eye stays above 21 mmHg without optic nerve damage or vision loss, raising the risk of glaucoma.
Ocular motor nerve palsies
Ocular motor nerve palsies are deficits of cranial nerves III, IV, and VI causing diplopia. Also called third, fourth, sixth nerve palsy. Causes include microvascular ischemia, inflammation, aneurysm, tumor; pupil-involving third palsy is an emergency.
Ocular myiasis
Ocular myiasis, or ophthalmomyiasis, is infestation of the eye or orbit by Diptera fly larvae, classified as external, internal, or orbital. Oestrus ovis, the sheep botfly, causes most external cases, treated by larval removal.
Ocular myopathy
Ocular myopathy, chiefly chronic progressive external ophthalmoplegia (CPEO), is a mitochondrial muscle disease causing progressive bilateral ptosis and eye-movement limitation without diplopia, distinguished from myasthenia gravis and thyroid eye disease.